-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Thematic Analysis
NewGeopolitics – Executive Briefing (First Edition)
Reasons to buy the ‘Geopolitics - Executive Briefing’ report: The report provides in-depth insights into the global geopolitical stance. Explore a global geopolitical risk map highlighting level of severity and a summary on the 2024 elections. Identify the frontline sectors exposed to global geopolitics. The report sheds light on the politics of the major countries that shape geopolitics. How is the ‘Geopolitics - Executive Briefing’ report different from other reports in the market? This executive briefing report explores the drivers...
-
Thematic Analysis
NewArtificial Intelligence – Executive Briefing (Third Edition) – Thematic Intelligence
This executive briefing helps you understand the impact of artificial intelligence on your business. It focuses on generative AI and the threats and opportunities it poses to every business across every sector.
-
Sector Analysis
Oil and Gas Final Investment Decisions (FIDs) in 2024, H1 Edition
Oil and Gas FIDs Market Report Overview The oil & gas FIDs market report H1 2024 edition provides valuable insights into the major projects targeted for FIDs in 2024 across the oil and gas value chain. Key Upstream Projects Targeting FIDs in 2024 Whiptail, Bonga North, Zama, South Lokichar Development (Phase 1), and Sea Lion Key Midstream Projects Targeting FIDs in 2024 Coral Norte Floating, Akwa Ibom Floating, Papua, Sonora Phase I Train III, Cedar Floating, and Brownsville Key Downstream...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Renizgamglogene Autogedtemcel in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Renizgamglogene Autogedtemcel in Sickle Cell Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Renizgamglogene Autogedtemcel in Sickle Cell Disease Drug Details: EDIT-301...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GSK-5462688 in Alpha-1 Antitrypsin Deficiency (A1AD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GSK-5462688 in Alpha-1 Antitrypsin Deficiency (A1AD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GSK-5462688 in Alpha-1 Antitrypsin Deficiency (A1AD) Drug Details: GSK-5462688 is under...
-
Product Insights
Net Present Value Model: Editas Medicine Inc’s EDIT-301
Empower your strategies with our Net Present Value Model: Editas Medicine Inc's EDIT-301 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KSQ-001 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KSQ-001 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KSQ-001 in Metastatic Melanoma Drug Details: KSQ-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KSQ-001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KSQ-001 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KSQ-001 in Solid Tumor Drug Details: KSQ-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KSQ-001 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KSQ-001 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KSQ-001 in Non-Small Cell Lung Cancer Drug Details: KSQ-001...